Skip to main content

Table 1 Survival at 4 years follow-up for burden of copy number alteration quartile sub-groups (Kaplan-Meier estimates)

From: Accumulation of copy number alterations and clinical progression across advanced prostate cancer

Clinical trial endpoint

Estimated survival (%)

Copy number alteration burden (Quartile)

Q1

Q2

Q3

Q4

Failure-free survival

63

36

29

31

Progression-free survival

77

50

40

43

Metastatic progression-free survival

82

57

45

43

Prostate cancer-specific survival

88

67

61

52

Overall survival

83

64

48

48

  1. Legend: range of copy number burdens (%) included in quartiles: (Q1: less than 10.55; Q2: 10.55–18.06; Q3: 18.06–27.03; Q4: 27.03–75.45)